Olema Pharmaceuticals Faces Investor Concerns Amid Stock Decline Olema Pharmaceuticals has reached a new 52-week low, trading at $3.94. The stock has declined by nearly 70% over six months, reflecting a challenging period for the biopharmaceutical firm. Analysts, however, maintain optimistic price targets ranging from $20 to $30, highlighting potential recovery opportunities driven by promising clinical trial results.123